[1]冯新霞,赵巍峰.精细化临床护理路径在抗病毒药物治疗慢性乙型肝炎患者中的应用价值[J].新乡医学院学报,2022,39(6):583-588.[doi:10.7683/xxyxyxb.2022.06.017]
　FENG Xinxia,ZHAO Weifeng.Application value of refined clinical nursing pathway in the antiviral therapy of patients with chronic hepatitis B[J].Journal of Xinxiang Medical University,2022,39(6):583-588.[doi:10.7683/xxyxyxb.2022.06.017]
点击复制

精细化临床护理路径在抗病毒药物治疗慢性乙型肝炎患者中的应用价值
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年6
页码:
583-588
栏目:
护理研究
出版日期:
2022-06-05

文章信息/Info

Title:
Application value of refined clinical nursing pathway in the antiviral therapy of patients with chronic hepatitis B
作者:
冯新霞; 赵巍峰
（新乡医学院第三附属医院感染性疾病科，河南　新乡　453003）
Author(s):
FENG Xinxia; ZHAO Weifeng
(Department of Infectious Diseases,the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453003,Henan Province,China)
关键词:
慢性乙型肝炎; 抗病毒药物; 临床护理路径; 精细化护理; 服药依从性
Keywords:
chronic hepatitis B; antiviral drug; clinical nursing pathway; reined nursing; medication compliance
分类号:
R473.73
DOI:
10.7683/xxyxyxb.2022.06.017
文献标志码:
A
摘要:
目的　探讨精细化临床护理路径（CNP）在抗病毒药物治疗慢性乙型肝炎（CHB）患者中的应用价值。方法　选择2019年1月至2021年1月新乡医学院第三附属医院收治的122例CHB患者为研究对象，采用随机数字表法将患者分为观察组和对照组，每组61例。所有患者给予抗病毒药物治疗，观察组患者在抗病毒药物治疗过程中给予精细化CNP干预，对照组患者给予常规护理干预，2组患者均干预6个月。干预前后，采用Mishel疾病不确定感量表（MUIS-A）评估患者的疾病不确定感，采用Zung焦虑量表（SAS）和抑郁自评量表（SDS）评估患者的心理状态，采用一般自我效能量表（GSES）评估患者的自我效能，采用Morisky药物依从性量表（MMAS-8）评估患者的服药依从性，采用慢性肝病问卷（CLDQ）评估患者的生活质量。结果　干预前2组患者MUIS-A评分比较差异无统计学意义（P>0.05），2组患者干预后MUIS-A评分显著低于干预前（P<0.05），且干预后观察组患者MUIS-A评分显著低于对照组（P<0.05）。干预前2组患者SAS、SDS评分比较差异无统计学意义（P>0.05），2组患者干预后SAS、SDS评分显著低于干预前（P<0.05），且干预后观察组患者SAS、SDS评分显著低于对照组（P<0.05）。干预前2组患者GSES评分比较差异无统计学意义（P>0.05），2组患者干预后GSES评分显著高于干预前（P<0.05），且干预后观察组患者GSES评分显著高于对照组（P<0.05）。干预前2组患者MMAS-8评分、服药依从性比较差异无统计学意义（P>0.05），2组患者干预后MMAS-8评分、服药依从性显著高于干预前（P<0.05）；干预后，观察组患者MMAS-8评分、服药依从性显著高于对照组（P<0.05）。干预前2组患者CLDQ评分比较差异无统计学意义（P>0.05），2组患者干预后CLDQ评分显著高于干预前（P<0.05）。干预后，2组患者系统症状、腹部不适得分比较差异无统计学意义（P>0.05），但观察组患者疲劳、活动能力、焦虑、情感功能得分及CLDQ总分显著高于对照组（P<0.05）。结论　精细化CNP可以有效减少抗病毒药物治疗CHB患者的疾病不确定感和不良情绪，提高患者的自我效能和服药依从性，改善患者的生活质量。
Abstract:
Objective　To investigate the application value of refined clinical nursing pathway (CNP) in the antiviral therapy of patients with chronic hepatitis B (CHB).Methods　A total of 122 CHB patients admitted to the Third Affiliated Hospital of Xinxiang Medical University from January 2019 to January 2021 were selected as the research subjects,and the patients were divided into the observation group and control group by random number table method,with 61 cases in each group.All patients were treated with antiviral drugs,and the patients in the observation group were treated with refined CNP intervention during the course of antiviral drug treatment,while the patients in the control group were treated with routine nursing intervention.All patients in both groups were intervened for 6 months.Before and after the intervention,the disease uncertainty of the patients was evaluated by Mishel′s uncertainty in illness scale-adult (MUIS-A),the psychological state of the patients was assessed by Zung self-rating anxiety scale (SAS) and self-rating depression scale (SDS),the self-efficacy of the patients was assessed by the general self-efficacy scale (GSES),the medication adherence was assessed by Morisky medication adherence scale(MMAS-8),and the patients′ quality of life was assessed by the chronic liver disease questionnaire (CLDQ).Results　There was no significant difference in the MUIS-A score of patients between the two groups before intervention (P>0.05).The MUIS-A scores of patients in the two groups after intervention were significantly lower than those before intervention (P<0.05).The MUIS-A scores of patients in the observation group were significantly lower than those in the control group (P<0.05).There was no significant difference in the SAS and SDS scores of patients between the two groups before intervention (P>0.05).The SAS and SDS scores of patients in the two groups after intervention were significantly lower than those before intervention(P<0.05).The SAS and SDS scores of patients in the observation group were significantly lower than those in the control group after intervention (P<0.05).There was no significant difference in the GSES score of patients between the two groups before intervention (P>0.05).The GSES score of patients in the two groups after intervention was significantly higher than that before intervention (P<0.05).The GSES score of patients in the observation group was significantly higher than that in the control group after intervention (P<0.05).There was no significant difference in the MMAS-8 score and medication compliance of patients between the two groups before intervention (P>0.05).The MMAS-8 score and medication compliance of patients in the two groups after intervention were significantly higher than those before intervention (P<0.05).The MMAS-8 score and medication compliance of patients in the observation group were significantly higher than those in the control group after intervention (P<0.05).There was no significant difference in the CLDQ scores between the two groups before intervention (P>0.05).The CLDQ scores of patients in the two groups after intervention were significantly higher than those before intervention (P<0.05).After intervention,there was no significant difference in the scores of system symptoms and abdominal discomfort of patients between the two groups (P>0.05),but the scores of fatigue,activity,anxiety,emotional function and CLDQ total score of patients in the observation group were significantly higher than those in the control group (P<0.05).Conclusion　The refined CNP can effectively reduce the disease uncertainty and negative emotions,enhance the self-efficacy and medication compliance,and improve the quality of life in CHB patients treated with antiviral drugs.

参考文献/References:

［1］　WHO.Global hepatitis report,2017［EB/OL］.(2017-04-19)［2021-07-15］.https://www.who.int/publications/i/item/9789241565455.
［2］　中华医学会感染病学分会，中华医学会肝病学分会.慢性乙型肝炎防治指南（2019年版）［J］.中华肝脏病杂志，2019，27（12）：938-961.
CHINESE SOCIETY OF INFECTIOUS DISEASES OF CHINESE MEDICAL ASSOCIATION,CHINESE SOCIETY OF HEPATOLOGY OF CHINESE MEDICAL ASSOCIATION.The guidelines of prevention and treatment for chronic hepatitis B (2019 version)［J］.Chin J Hepatol,2019,27(12):938-961.
［3］　刘芳，周琴，王印伟.临床护理路径在核苷类抗病毒药物治疗的慢性乙型肝炎患者护理中的应用［J］.检验医学与临床，2020，17（14）：2073-2075.
LIU F,ZHOU Q,WANG Y W.Application of clinical nursing pathway in nursing of chronic hepatitis B patients treated with nucleoside antiviral drugs［J］.Lab Med Clin,2020,17(14):2073-2075.
［4］　曾志童，王朝昕，王慧，等.基于国内外最新指南的慢性病个体化、精细化健康管理服务分析及我国发展前景：以糖尿病为例［J］.中国全科医学，2021，24（9）：1037-1044.
ZENG Z T,WANG Z X,WANG H,et al.Individualized and precision health management for diabetes:evidence from the latest guidelines and development prospects in China［J］.Chin Gen Pract,2021,24 (9):1037-1044.
［5］　麦嘉轩，邓叶青，谢婉花.疾病不确定感量表发展现状［J］.实用医学杂志，2013，29（12）：2053-2055.
MAI J X,DENG Y Q,XIE W H.Development status of illness uncertainty scale［J］.J Pract Med,2013,29 (12):2053-2055.
［6］　段泉泉，胜利.焦虑及抑郁自评量表的临床效度［J］.中国心理卫生杂志，2012，26（9）：676-679.
DUAN Q Q,SHENG L.Differential validity of SAS and SDS among psychiatric non-psychotic outpatients and their partners［J］.Chin Ment Health J,2012,26 (9):676-679.
［7］　施俊琦，王垒.一般性自我效能量表的信效度检验［J］.中国心理卫生杂志，2005，19（3）：191-193.
SHI J Q,WANG L.Reliability and validation of the general self-efficacy scale［J］.Chin Ment Health J,2005,19 (3):191-193.
［8］　侯凯旋，闫素英.慢病患者药物依从性量表的研究［J］.中国医院药学杂志，2018，38（2）：192-196.
HOU K X,YAN S Y.A review of medication adherence scale in patients with chronic diseases［J］.Chin J Hosp Pharm,2018,38 (2):192-196.
［9］　吴创鸿，邓启文，纪晓抒，等.慢性肝病问卷在慢性乙型肝炎患者中的试用［J］.中国临床心理学杂志，2003，11（1）：60-62.
WU C H,DENG Q W,JI X S,et al.Preliminary use of the CLDQ in chronic hepatitis B patients［J］.Chin J Clin Psychol,2003,11 (1):60-62.
［10］　PAPATHEODORIDI M,PAPATHEODORIDIS G.New concepts regarding finite oral antiviral therapy for HBeAg-negative chronic hepatitis B［J］.J Hepatol,2021,75(6):1495-1496.
［11］　DURAISAMY G S,BHOSALE D,LIPENSK I,et al.Advanced therapeutics,vaccinations,and precision medicine in the treatment and management of chronic hepatitis B viral infections.Where are we and where are we going［J］.Viruses,2020,12(9):998.
［12］　DAIDA Y G,BOSCARINO J A,MOORMAN A C,et al.Mental and physical health status among chronic hepatitis B patients［J］.Qual Life Res,2020,29(6):1567-1577.
［13］　RISTEVSKI E,LUDWICK T,LEACH M,et al.Implementing optimal care pathways for aboriginal and torres strait islander people with cancer:a survey of rural health professionals′ self-rated learning needs［J］.Int J Integr Care,2022,22(1):27.
［14］　朱兰，张六一.临床护理路径应用于冠状动脉粥样硬化性心脏病患者介入治疗效果的meta分析［J］.中国卫生资源，2021，24（2）：185-189，198.
ZHU L,ZHANG L Y.Meta-analysis of clinical nursing pathway applied to interventional therapy for patients with coronary atherosclerotic heart disease［J］.Chin Health Res,2021,24 (2):185-189,198.
［15］　STONE L,OLSEN A.Illness uncertainty and risk management for people with cancer［J］.Aust J Gen Pract,2022,51(5):321-326.
［16］　许丽红，王苗苗，李静，等.HBV/HCV相关肝病住院患者再定义疾病不确定感与应对方式的相关性研究［J］.中华现代护理杂志，2021，27（35）：4856-4860.
XU L H,WANG M M,LI J,et al.Correlation between redefined disease uncertainty and coping style in hospitalized patients with HBV/HCV-related liver disease［J］.Chin J Mod Nurs,2021,27 (35):4856-4860.
［17］　王小洪，朱妍，张华，等.慢性乙型肝炎患者心理一致感、应对方式对疾病不确定感的影响［J］.护理实践与研究，2020，17（20）：47-49.
WANG X H,ZHU Y,ZHANG H,et al.Effect of psychological consistency and coping style on the uncertainty of illness in patients with chronic hepatitis B［J］.Nurs Pract Res,2020,17 (20):47-49.
［18］　PARAGAS E D JR,BARCELO T I.Effects of message-framed informational videos on diabetes management knowledge and self-efficacy［J］.Int J Nurs Pract,2019,25(4):e12737.
［19］　ALMUTARY H,TAYYIB N.Factors associated with exercise self-efficacy among people with chronic diseases［J］.Appl Nurs Res,2020,54:151275.
［20］　马冰，白黎.提升自我效能的护理干预对慢性乙型肝炎患者治疗依从性、心理状况的影响［J］.国际护理学杂志，2020，39（12）：2169-2171.
MA B,BAI L.Effect of nursing intervention of improving self-efficacy on treatment compliance and psychological status of patients with chronic hepatitis B［J］.Int J Nurs,2020,39 (12):2169-2171.

相似文献/References:

[1]何玉洁,袁翠云,石惠琴.苦参素联合拉米夫定治疗慢性乙肝疗效观察[J].新乡医学院学报,2003,20(01):040.
[2]刘朝阳,魏素云,于培龙.氧化苦参碱联合拉米夫定治疗慢性乙型肝炎疗效观察[J].新乡医学院学报,2003,20(01):041.
[3]何玉洁,袁翠云,石惠琴.苦参素联合拉米夫定治疗慢性乙肝疗效观察[J].新乡医学院学报,2003,20(01):040.
[4]刘朝阳,魏素云,于培龙.氧化苦参碱联合拉米夫定治疗慢性乙型肝炎疗效观察[J].新乡医学院学报,2003,20(01):041.
[5]吕福鸣,许青田,李蒙军.慢性乙型肝炎患者血清HBV DNA定量检测与抗原抗体模式的关系 [J].新乡医学院学报,2006,23(03):000.
[6]张高峰,翟自霞.大学新生慢性乙型肝炎患者心理健康状况分析[J].新乡医学院学报,2011,28(06):000.
[7]李银彩.血府逐淤汤联合干扰素对慢性乙型肝炎肝硬化患者肝纤维化及门静脉血流动力学的影响[J].新乡医学院学报,2012,29(08):615.
[8]向保云１,李红德１,徐江海１,等. 肿瘤坏死因子-α和白细胞介素-１β在慢性乙型肝炎和原发性肝癌患者血清及肝组织中的表达 [J].新乡医学院学报,2014,31(12):999.[doi:10.7683/xxyxyxb.2014.12.009]
[9]徐鹏卫,代克强,卢建国,等.流行性感冒防控新策略研究进展[J].新乡医学院学报,2017,34(11):955.[doi:10.7683/xxyxyxb.2017.11.001]
[10]王　蕾,王　丹,李汝珂,等.“五个时刻法”延续用药指导在慢性乙型肝炎长期抗病毒治疗中的应用价值[J].新乡医学院学报,2021,38(6):526.[doi:10.7683/xxyxyxb.2021.06.006]
　WANG Lei,WANG Dan,LI Ruke,et al.Application value of "5-moment method" continuous medication guidance in long-term antiviral therapy of chronic hepatitis B[J].Journal of Xinxiang Medical University,2021,38(6):526.[doi:10.7683/xxyxyxb.2021.06.006]

更新日期/Last Update: 2022-06-05